#ASTX660
Pleased to share that our recent Phase I clinical trial of tolinapant (ASTX660) combined with pembrolizumab in advanced solid tumours has been selected for the Nature Communications Editors’ Highlights – Cancer collection!

www.nature.com/articles/s41...
#CancerResearch #Immunotherapy
www.nature.com
October 14, 2026 at 9:20 PM
Results from an open label, multicenter phase I #trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of #ASTX660 in combination with the anti-PD-1 antibody #pembrolizumab for solid #tumors doi.org/10.1038/s414...
IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial - Nature Communications
The IAP antagonist ASTX660 has the potential to enhance cancer immunotherapy by sensitizing tumour cells to immune-mediated killing. Here, the authors report results from an open-label, multicentre ph...
doi.org
October 6, 2026 at 10:22 AM